2. Feehally J., Cameron J.S. IgA nephropathy: progress before and since Berger. Am. J. Kidney Dis. 2011;58(2):310–9. doi: 10.1053/j.ajkd.2011.03.024.

3. Floege J., Rauen T., Tang S.C.W. Current treatment of IgA nephropathy. Semin. Immunopathol. 2021;43(5):717–28. doi: 10.1007/s00281-021-00888-3.

4. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100:S1–276.

5. Клинические рекомендации «Гломерулярные болезни: иммуноглобулин А нефропатия» 2021 г. Национальная Ассоциация Нефрологов. https://rusnephrology.org/wp-content/uploads/2021/04/iga_060421-1.pdf.

6. 6. Huang X., Xu G. An Update on Targeted Treatment of IgA Nephropathy: An Autoimmune Perspective. Front. Pharmacol. 2021;12:715253. doi: 10.3389/ fphar.2021.715.

7. Гуляев С.В., Стрижаков Л.А., Чеботарева Н.В., Моисеев С.В. Роль MALT-системы кишечника в патогенезе IgA-нефропатии. Тер. архив. 2021;93(6):724–8. doi: 10.26442/00403660.2021.06.200868.

8. Nishiyama A., Konishi Y., Ohashi N., et al. Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrol. Dial. Transplant. 2011;26(1):170–7. doi: 10.1093/ndt/gfq371.

9. Stefanski A., Schmidt K.G., Waldherr R., Ritz E. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int. 1996;50(4):1321–6. doi: 10.1038/ki.1996.444.

10. Reich H.N., Troyanov S., Scholey J.W., Cattran D.C; Toronto Glomerulonephritis Registry. Remission of proteinuria improves prognosis in IgA nephropathy. J. Am. Soc. Nephrol. 2007;18(12):3177–83. doi: 10.1681/ ASN.2007050526.

11. Praga M., Gutiérrez E., González E., et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J. Am. Soc. Nephrol. 2003;14(6):1578–83. doi: 10.1097/01.asn.0000068460.37369.dc.

12. Li P.K., Leung C.B., Chow K.M., et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am. J. Kidney Dis. 2006;47(5):751–60. doi: 10.1053/j.ajkd.2006.01.017.

13. Le W., Liang S., Hu Y., et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol. Dial. Transplant. 2012;27(4):1479–85. doi: 10.1093/ndt/gfr527.

14. Kanno Y., Okada H., Saruta T., et al. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a3-year follow-up. Clin. Nephrol. 2000;54:360–5.

15. Russo D., Pisani A., Balletta M.M., et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am. J. Kidney Dis. 1999;33(5):851–6. doi: 10.1016/ s0272-6386(99)70416-6.

16. Russo D., Minutolo R., Pisani A., et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J. Kidney Dis. 2001;38(1):18–25. doi: 10.1053/ajkd.2001.25176.

17. Lennartz D.P., Seikrit C., Wied S., et al. Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy. J. Nephrol. 2020;33(6):1231–9. doi: 10.1007/s40620-020-00836-8.

18. Tang S.C., Lin M., Tam S., et al. Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study. Nephrol. Dial. Transplant. 2012;27(2):613–8. doi: 10.1093/ndt/gfr349.

19. Szeto C.C., Kwan B.C., Chow K.M., et al. The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study. PLoS One. 2013;8(5):e62736. Published 2013 May 10. doi: 10.1371/journal.pone.0062736.

20. Heerspink H.J., Perkins B.A., Fitchett D.H., et al. Sodium Glucose Cotransporter2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016;134(10):752–72. doi: 10.1161/CIRCULATIONAHA.116.021887.

21. Cherney D.Z.I., Dekkers C.C.J., Barbour S.J., et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

22. Wheeler D.C., Toto R.D., Stefánsson B.V., et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100(1): 215–24. doi: 10.1016/j.kint.2021.03.033.

23. Barratt J., Floege J. SGLT-2 inhibition in IgA nephropathy: the new standard of care? Kidney Int. 2021;100(1):24–6. doi: 10.1016/j.kint.2021.04.002.

24. Herrington W.G., Staplin N., Wanner C., et al., EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2022 Nov 4. doi: 10.1056/NEJMoa2204233.

25. Grande J.P., Donadio J.V. Dietary fish oil supplementation in IgA nephropathy: a therapy in search of a mechanism? Nutrit. 1998;14(2):240–2. doi: 10.1016/s0899-9007(97)00437-1.

26. Donadio J.V., Bergstralh E.J., Offord K.P., et al. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N. Engl. J. Med. 1994;331(18):1194–9. doi: 10.1056/NEJM199411033311804.

27. Donadio J.V., Grande J.P., Bergstralh E.J., et al. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J. Am. Soc. Nephrol. 1999;10(8):1772–7. doi: 10.1681/ASN.V1081772

28. Hogg R.J., Lee J., Nardelli N., et al. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin. J. Am. Soc. Nephrol. 2006;1(3):467–74. doi: 10.2215/CJN.01020905.

29. Strippoli G.F., Manno C., Schena F.P. An "evidence-based" survey of therapeutic options for IgA nephropathy: assessment and criticism. Am. J. Kidney Dis. 2003;41(6):1129–39. doi: 10.1016/s0272-6386(03)00344-5.

30. Taji Y., Kuwahara T., Shikata S., Morimoto T. Meta-analysis of antiplatelet therapy for IgA nephropathy. Clin. Exp. Nephrol. 2006;10(4):268–73. doi: 10.1007/s10157-006-0433-8.

31. Liu X.J., Geng Y.Q., Xin S.N., et al. Antithrombotic drug therapy for IgA nephropathy: a meta analysis of randomized controlled trials. Intern. Med. 2011;50(21):2503–10. doi: 10.2169/internalmedicine.50.5971.

32. Kuo K.L., Hung S.C., Tseng W.C., et al. Dipyridamole decreases dialysis risk and improves survival in patients with pre-dialysis advanced chronic kidney disease. Oncotarget. 2017;9(4):5368–77.

33. Harabuchi Y., Takahara M. Recent advances in the immunological understanding of association between tonsil and immunoglobulin A nephropathy as a tonsil-induced autoimmune/inflammatory syndrome. Immun. Inflamm. Dis. 2019;7(2):86–93. doi: 10.1002/iid3.248.

34. Hotta O., Miyazaki M., Furuta T., et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy Am. J. Kidney Dis. 2001;38(4):736–43. doi: 10.1053/ajkd.2001.27690.

35. Xie Y., Nishi S., Ueno M., et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int. 2003;63(5):1861–7. doi: 10.1046/j.1523-1755.2003.00935.x.

36. Hirano K., Matsuzaki K., Yasuda T., et al. Association Between Tonsillectomy and Outcomes in Patients With Immunoglobulin A Nephropathy. JAMA. Netw. Open. 2019;2(5):e194772.

37. Duan J., Liu D., Duan G., Liu Z. Long term efficacy of tonsillectomy as a treatment in patients with IgA nephropathy: a meta-analysis. Int. Urol. Nephrol. 2017;49(1):103–12. doi: 10.1007/s11255-016-1432-7.

38. Rasche F.M., Schwarz A., Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin. Nephrol. 1999;51:147–52.

39. Piccoli A., Codognotto M., Tabbi M.G., et al. Influence of tonsillectomy onthe progression of mesangioproliferative glomerulonephritis. Nephrol. Dial. Transplant. 2010;25(8):2583–9. doi: 10.1093/ndt/gfq107.

40. Kovacs T., Vas T., Kovesdy C.P., et al. Effect of tonsillectomy and its timing on renal outcomes in Caucasian IgA nephropathy patients. Int. Urol. Nephrol. 2014;46(11):2175–82. doi: 10.1007/s11255-014-0818-7.

41. Liu L.L., Wang L.N., Jiang Y., et al. Tonsillectomy for IgA Nephropathy: a meta-analysis. Am. J. Kidney Dis. 2015;65(1):80–7. doi: 10.1053/ j.ajkd.2014.06.036.

42. Komatsu H., Fujimoto S., Hara S., et al. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin. J. Am. Soc. Nephrol. 2008;3(5):1301–7. doi: 10.2215/CJN.00310108.

43. Wang Y., Chen J., Wang Y., et al. A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy. Nephrol. Dial. Transplant. 2011;26(6):1923–31. doi: 10.1093/ndt/gfq674.

44. Добронравов В.А., Кочоян З.Ш., Мужецкая Т.О., Лин Д.И. Анализ эффективности терапии иммуноглобулин А нефропатии. Тер. архив 2020;92(6):23–32. doi: 10.26442/00403660.2020.06.000669.

45. Aratani S., Matsunobu T., Shimizu A., et al. Tonsillectomy Combined With Steroid Pulse Therapy Prevents the Progression of Chronic Kidney Disease in Patients With Immunoglobulin A (IgA) Nephropathy in a Single Japanese Institution. Cureus 2021;13(6):e15736. doi: 10.7759/cureus.157.

46. Kawamura T., Yoshimura M., Miyazaki Y., et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol. Dial. Transplant. 2014;29(8):1546–53. doi: 10.1093/ndt/gfu020.

47. Coppo R. The gut-renal connection in IgA nephropathy. Semin. Nephrol. 2018;38:504–12. https://doi.org/10.1016/j. semnephrol.2018.05.020.

48. De Angelis M., Montemurno E., Piccolo M., et al. (2014) Microbiota and Metabolome Associated with Immunoglobulin A Nephropathy (IgAN). PLoS ONE. 2014;9(6):e99006. doi: 10.1371/journal.pone.0099006.

49. Lauriero G., Abbad L., Vacca M. et al. Fecal Microbiota Transplantation Modulates Renal Phenotype in the Humanized Mouse Model of IgA Nephropathy. Front. Immunol. 2021;12:694787. doi: 10.3389/fimmu.2021.694787.

50. Zhao J., Bai M., Yang X., et al. Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports. Renal. Failure. 2021;43(1):928–33. doi: 10.1080/0886022X.2021.1936038.